



NEWS

We are proud to inform you that DVSSciences Inc. is now represented in Asia by IAS Inc.

[To the NEWS SUMMARY](#)

We are proud to inform you that DVSSciences Inc. is now represented in Asia by IAS Inc.



DVS Sciences Inc.
70 Peninsula Cres.
Richmond Hill
Ontario, L4S 1Z5
Canada
Phone: (416)-946-8850

**DVSSciences Inc.
is represented in Asia
by IAS Inc.**



IAS Inc.
5th Floor LOFTY Kunitachi, 2-14-1
Fujimidai, Kunitachi, Tokyo
Japan 186-0003
Phone: (81)-42-577-1044
Fax: (81)-3-4570-0341
info_ias@iasinc.jp

[DVSSciences Inc.](#) is an analytical equipment and reagents development company that produce and market globally the [CYTOF™](#), a high throughput mass cytometer for individual cell analysis based on a novel elemental mass-spectrometry detection technology, and the [MAXPAR™](#) system of novel reagents related to massively multi-parametric biological assays.

[IAS Inc.](#) was established in 2004 and the principals of IAS Inc. have more than 70 years of combined experience in the ICP-MS technology. Two of the principals worked with the researchers of DVS Sciences while they worked at PerkinElmer Sciex in Toronto. IAS Inc. is especially well known in the semiconductor market in Asia Pacific region as well as Japan and now expands into the cytometry market.

[Mass Cytometry](#) is a technology that addresses applications that are typically run by flow cytometer analyzers, but extends the capability to many simultaneous parameters. The detection technology is based on atomic mass spectrometry (the state of the art technology for the determination of the elemental composition of materials, but heretofore foreign to biologists). Hence, it offers the specificity, dynamic range and quantitative capability of mass spectrometry in a format that is familiar to flow cytometry practitioners.



Instead of using optical probes (fluorophores or quantum dots) to identify biomarkers, [DVSSciences Inc.](#) uses elements or stable isotopes. There are more than 70 available elements and stable isotopes that are suitable for the application. The technology addresses an urgent need for improvement of detection and characterization of rare cells in complex samples (e.g., cancer cells in blood). This represents the state of the art that will transform research into the genesis of disease, facilitate drug discovery and enable unprecedented early stage personalized disease diagnosis.

Please, contact info_ias@iasinc.jp directly and be updated on all exciting [News](#) related to this novel technology. Download [Brochure](#) and see the research [References](#) !

[To the NEWS SUMMARY](#)